Immix Biopharma Inc. (IMMX): Utang marang Ekuitas

Logo korporat perusahaan Immix Biopharma (IMMX)

The prospects for Immix Biopharma, Inc. (IMMX) depend on upcoming tests of new methods for combating autoimmune diseases, while the speculative nature of this micro-cap is already priced in. This chart on GURU.Markets shows that the total debt-to-equity ratio is 0.00, a critical factor given the risk of shareholder dilution due to R&D costs. Meanwhile, operational processes are protected by outsourcing vaccine production to third-party facilities.

IMMX: Rasio Total Utang marang Ekuitas Immix 04.07.2022 - 30.10.2026

Rincian metrik komprehensif lan analitis Immix Biopharma (IMMX)

- rega lan prakiraan konsensus rega:
Bagan rega Immix Biopharma Inc.|IMMX - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Nilai pasar Immix Biopharma|IMMX - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Immix Biopharma|IMMX - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku immixbio.com|IMMX - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Immix Biopharma, Inc.|IMMX - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Immix Biopharma Inc.|IMMX - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Immix Biopharma|IMMX - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Immix Biopharma|Indikator likuiditas cepet immixbio.com
- informasi bathi lan kelipatan valuasi:
IMMX - Bathi pungkasan
Analisis fundamental perusahaan:Immix Biopharma, Inc., IMMX
Barang utama Immix Biopharma Inc.

Investors must balance growth potential against debt load to mitigate bankruptcy risks during periods of profit stagnation. By analyzing changes in the total debt-to-equity ratio, you assess the proportion of borrowed funds within the asset structure of Immix Biopharma, Inc. (IMMX), which is critical for maintaining the costly IMX-110 platform and expanding the network of specialized oncology centers within a closed medical circuit.

Pesaing Immix Biopharma, Inc. (IMMX)

Utang marang Ekuitas ImmunityBio|Utang marang Modal Immunocore Holdings IMCR|Utang marang Ekuitas Janux Pharma (JANX)|Arcus Corp - Rasio Utang marang Ekuitas|Total Utang marang Modal ZYME (Zymeworks Inc.)|TNGX - Rasio Total Utang marang Ekuitas|IOVA - Utang marang Ekuitas|Utang marang Modal Immatics NV|Xencor Corp (XNCR) - Utang marang Ekuitas|CMPX (Compass Therapeutics Corp) - Utang marang Ekuitas|Utang marang Ekuitas Replimune Group, Inc.|Utang marang Modal lyell.com LYEL|Total Utang marang Modal IPHA|pyxisoncology.com (PYXS) - Rasio Utang marang Modal|Compugen - Rasio Total Utang marang Ekuitas|IO Biotech Inc. (IOBT) - Utang marang Modal|STRO: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi INKT (minktherapeutics.com)|HOWL: Total Utang marang Modal|ALXO - Koefisien Total Utang marang Modal|Utang marang Ekuitas Cue Biopharma, Inc.|Rasio Total Utang marang Ekuitas PDS Biotechnology Corp (PDSB)|Utang marang Ekuitas Sonnet BioTherapeutics (SONN)|Rasio Total Utang marang Ekuitas MAIABiotech.com MAIA|Liminatus Pharma LLC - Rasio Total Utang marang Ekuitas|Total Utang marang Modal LAVA Therapeutics NV LVTX|NXTC - Utang marang Ekuitas|LPTX (Leap Therapeutics, Inc.) - Rasio Utang marang Ekuitas|intensitytherapeutics.com (INTS) - Utang marang Ekuitas|Utang marang Modal Sensei Biotherapeutics, Inc. (SNSE)|Rasio Total Utang marang Ekuitas TOVX|GRTS - Rasio Utang marang Modal|Rasio Total Utang marang Ekuitas KA (Kineta Bio)|Utang Agregat marang Modal NEXI|Total Utang marang Modal TSBX (Turnstone Biologics Corp.)|Rasio Kabeh Utang marang Dana Pribadi VCNX|Harpoon Therapeutics, Inc. - Total Utang marang Modal